VIMENTIN EXPRESSION IN HUMAN CELL LINES OF EPITHELIAL TUMORS

Background. Cell cultures used as a models in studies of epithelial tumors, are obtained not only from solid tumors, but also from extracellular fluids. It is known that dissemination of ovarian cancer in the peritoneum and further growth of tumor cells in ascetic liquid is accompanied with the activation of epithelial-mesenchymal transition, and, therefore, cell cultures derived from extracellular fluids can have a distinct molecular phenotype from primary tumors.

Objective: evaluation the “persistence” of epithelial phenotype in breast and ovarian cancer cell cultures.

Materials and methods. The cells obtained from pleural fluid (MCF-7, T-47D), colostrum (HBL-100), solid tumors (BT-474, HCC1937) of patients with breast cancer and ascitic fluid (SCOV- 3) of patients with ovarian cancer. The expression of cytokeratins and vimentin was evaluated using a quantitative immunofluorescence method associated with flow cytometry.

Results. Vimentin expression in cells derived from extracellular fluids was not changed (line HBL-100), slightly decreased (SCOV-3 cells), or even was lost (MCF-7 and T-47D cells). HCC1937 cells obtained from solid tumor with expected low expression of vimentin acquired a molecular phenotype with a high expression of this mesenchymal marker. In breast cancer cells BT-474 derived from solid tumor a “persistence” of epithelial phenotype was discovered.

Conclusion. Quantitative assessment of the de novo expression of mesenchymal protein vimentin showed that the tumor phenotype within the organizm is not always realized in cells adapted to growth in culture, and is not always «strictly» epithelial, and this evidence must be considered with different kinds of molecular studies of epithelial cells in vitro.

1. Davidson B., Holth A., Hellesylt E. et al. The clinical role of epithelial mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions. Hum Pathol 2015;46(1):1–8. DOI: 10.1016/j.humpath.2014.10.004. PMID: 25455994.

2. Choi Y., Lee H. J., Jang M. H. et al. Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer. Hum Pathol 2013;44(11):2581–9. DOI: 10.1016/j.humpath.2013.07.003. PMID: 24055090.

3. Heerboth S., Housman G., Leary M. et al. EMT and tumor metastasis. Clin Transl Med 2015;26(4):1–13. DOI: 10.1186/s40169-015-0048-3. PMID: 25852822.

4. Savagner P., Kusewitt D. F., Carver E. A. et al. Developmental transcription factor slug is required for effective reepithelialization by adult keratinocytes. J Cell Physiol 2005;202(3):858–66. DOI: 10.1002/jcp.20188. PMID: 15389643.

5. Thiery J. P., Acloque H., Huang R. Y., Nieto M. A. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139(5):871–90. DOI: 10.1016/j.cell.2009.11.007. PMID: 19945376.

6. Cao L., Shao M., Schilder J. et al. Tissue transglutaminase links TGF-β, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene 2012;31(20):2521–34. DOI: 10.1038/onc.2011.429. PMID: 21963846.

7. Wu D. I., Liu L., Ren C. et al. Epithelialmesenchymal interconversions and the regulatory function of the ZEB family during the development and progression of ovarian cancer. Oncol Lett 2016;11(2):1463–8. DOI: 10.3892/ol.2016.4092. PMID: 26893761.

8. Nieto M. A. Epithelial plasticity: a common theme in embryonic and cancer cells. Science 2013;8(342):1–7. DOI: 10.1126/science.1234850. PMID: 24202173.

9. Tsai J. H., Donaher J. L., Murphy D. A. et al. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 2012;22(6):725–36. DOI: 10.1016/j.ccr.2012.09.022. PMID: 23201165.

10. Klymenko Y., Kim O., Stack M. S. Complex determinants of epithelial: mesenchymal phenotypic plasticity in ovarian cancer. Cancers (Basel) 2017;9(8):1–32. DOI: 10.3390/cancers9080104. PMID: 28792442.

11. Hay E. D. The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it. Dev Dyn 2005;233(3):706–20. DOI: 10.1002/dvdy.20345. PMID: 15937929.

12. Kidd M. E., Shumaker D. K., Ridge K. M. The role of vimentin intermediate filaments in the progression of lung cancer. Am J Respir Cell Mol Biol 2014;50(1):1–6. DOI: 10.1165/rcmb.2013-0314TR. PMID: 23980547.

13. Bogush T. A., Kalyuzhnyy S. A., Dudko E. A. et al. Molecular peculiarities of ascitic ovarian cancer cells revealing by immunofluorescence assay involving flow cytometry. Vestnik Moskovskogo Universiteta. Ser. 2. Khimiya = Moscow State University Bulletin, Ser. 2, Chemistry 2016;57(5):330–5. (In Russ.].

14. Bogush T. A., Shaturova A. S., Dudko E. A. et al. Quantitative immunofluorescent estimation of estrogen receptor β expression in human solid tumors using flow cytometry. Vestnik Moskovskogo Universiteta. Ser. 2. Khimiya = Moscow State University Bulletin, Ser. 2, Chemistry 2011;52(4):305–12. (In Russ.).

15. 15. Bai F., Chan H. L., Scott A. et al. BRCA1 suppresses epithelial-to-mesenchymal transition and stem cell dedifferentiation during mammary and tumor development. Cancer Res 2014;74(21):6161–72. DOI: 10.1158/0008–5472.CAN-14-1119. PMID: 25239453. 16.

16. Strauss R., Li Z. Y., Liu Y. et al. Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS One 2011;6(1):1–20. DOI: 10.1371/journal.pone.0016186. PMID: 21264259. 17.

17. Bezdieniezhnykh N., Lykhova A., Semesiuk N. et al. Establishment and characterization of new breast and ovarian cancer cell lines as a model for studying cellular plasticity in vitro. Exp Oncol 2016;38(2):94–100. PMID: 27356577.